Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208)
Fast, easy summary view of NICE guidance on 'gastrointestinal cancers'
NICE recommends trastuzumab as a possible treatment for some people (see below) with a type of HER2-positive metastatic gastric cancer called adenocarcinoma.
Who can have trastuzumab?
You should be able to have trastuzumab if:
- you have a type of cancer that scores three when tested for HER2 and
- you have not had treatment for metastatic gastric cancer before.
You can ask your healthcare professional to explain HER2 testing.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: gastrointestinal cancers
This page was last updated: 06 February 2014
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA208 Trastuzumab i drin canser gastrig metastatig: deall canllawiau NICE (fformat MS Word)
Information for the public
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.